Overview

Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To establish the role of ketamine in hospitalized terminally ill cancer patients with refractory cancer pain, using continuous intravenous infusion of ketamine
Phase:
Phase 2
Details
Lead Sponsor:
Pusan National University Yangsan Hospital
Treatments:
Ketamine